Pre-clinical and clinical significance of heparanase in Ewing's sarcoma.
Shafat
Itay
I
Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Ben-Arush
Myriam Weyl
MW
Issakov
Josephine
J
Meller
Isaac
I
Naroditsky
Inna
I
Tortoreto
Monica
M
Cassinelli
Giuliana
G
Lanzi
Cinzia
C
Pisano
Claudio
C
Ilan
Neta
N
Vlodavsky
Israel
I
Zunino
Franco
F
D000328:Adult; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D005966:Glucuronidase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006493:Heparin / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009361:Neoplasm Invasiveness; D012512:Sarcoma, Ewing / Q000201:enzymology* / Q000473:pathology; D013347:Subcellular Fractions / Q000187:drug effects / Q000201:enzymology; D016896:Treatment Outcome; D000099175:Heparanase
D004791:Enzyme Inhibitors; D016222:Fibroblast Growth Factor 2; D005346:Fibroblast Growth Factors; D005966:Glucuronidase; D006493:Heparin; D000099175:Heparanase; C559639:SST 0001